sur Fresenius SE & Co. KGaA (ETR:FRE)
Fresenius Appoints Mahl to Management Board and Extends Hennicken’s Contract
The Supervisory Board of Fresenius SE & Co. KGaA has appointed Dr. Marc-Alexander Mahl to the Management Board, effective November 1, 2026. Mahl will oversee the Fresenius Kabi businesses, succeeding Pierluigi Antonelli. Alongside this, Sara Hennicken’s role as Chief Financial Officer (CFO) has been extended for an additional five years, securing her position until 2032.
Marc-Alexander Mahl, a seasoned executive with over 20 years at Fresenius, will continue to lead the Pharma Business Unit amidst growing strategic importance. His expanded role includes supervision over the Nutrition business, now directed by Sébastien Guery. Guery, having held various management positions at international companies, will report directly to Mahl.
These leadership changes align with Fresenius's #FutureFresenius initiative, emphasizing sustainable and profitable growth. The company is positioning its leadership team for future challenges and opportunities, focusing on innovation-driven growth within the Biopharma, MedTech, and Nutrition sectors.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Fresenius SE & Co. KGaA